Clinical trials: Malignancy, Hematologic, open to volunteers
Chronic Lymphocytic Leukemia
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Background: The drug venetoclax treats chronic lymphocytic leukemia (CLL). Researchers want to find better treatments for CLL. To do that, they need to learn how the drug affects CLL cancer cells and the immune system.
- Trial name
- NCT03986034
- Testing
- During Venetoclax
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Newly Diagnosed Multiple Myeloma
A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
This study aims to evaluate the safety and efficacy of Linperlisib combined with the VRD regimen in the treatment of newly diagnosed patients with multiple myeloma.
- Trial name
- NCT06799676
- Testing
- a combination treatment of Linperlisib and the VRD regimen
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Fuling Zhou
GVHD, Hematopoietic Cell Transplantation (HCT)
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT).
- Conditions
- GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes
- Trial name
- NCT07302776
- Testing
- Tacrolimus, Early Tacrolimus Taper Strategy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Acute Myeloid Leukemia, Leukemia
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute…
- Trial name
- NCT06824168
- Testing
- Quizartinib High Dose, Quizartinib Low Dose
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 130 people
- Sponsor
- Daiichi Sankyo
Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Real-world Study of Acalabrutinib
The primary purpose of this study is to describe acotinib treatment patterns in Chinese patients with CLL/SLL and MCL who received acotinib according to the label.
- Trial name
- RESA (NCT06767891)
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Ruijin Hospital
Lymphocytic Leukemia
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: Personalized NeoAntigen Vaccine Poly-ICLC…
- Trial name
- NCT03219450
- Testing
- NeoVax, Cyclophosphamide, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Acute Lymphoblastic
Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the most common malignant disease among children. Treatment results have improved over time due to intensive risk-adapted therapy and the 5-year survival rate is now above 90%.
- Trial name
- NCT04209244
- Testing
- Eskimo-3 Pure Fish Oil, Rapeseed Oil
- Where
- 4 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Relapsed or Refractory Multiple Myeloma (RRMM)
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07579234
- Testing
- F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT06083207
- Testing
- IBI3003
- Where
- 13 sites in Australia, China
- Volunteers
- 116 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Relapsed or Refractory Multiple Myeloma
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
The purpose of this study is to characterize the safety of QLS4131 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS4131 injection in participants with relapsed…
- Trial name
- NCT06500507
- Testing
- QLS4131 Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
AML, NHL
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
This is a single-arm, open-label, dose-escalation and dose-expansion phase I clinical trial aimed at assessing the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary efficacy of FD-001 capsules in the…
- Trial name
- NCT06731699
- Testing
- FD-001
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Chengdu FenDi Pharmaceutical Co., Ltd.
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease.
- Conditions
- T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT07220993
- Testing
- CD7.CAR/28zeta T Cells
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Chronic Myeloid Leukemia
Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
This study is a multicenter observational study aimed to investigate the efficacy and safety of olverembatinib dose reduction to 20 mg every other day (QOD) in patients with chronic myeloid leukemia (CML) in chronic phase or…
- Trial name
- NCT07383298
- Testing
- Olverembatinib 20mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qian Jiang
Multiple Myeloma
Selinexor and Backbone Treatments of Multiple Myeloma Patients
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma…
- Trial name
- STOMP (NCT02343042)
- Testing
- Selinexor, Dexamethasone, Lenalidomide
- Where
- 25 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Karyopharm Therapeutics Inc
Acute Lymphoid Leukemia (ALL)
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
This single-arm, prospective, multicenter, phase II study will enroll newly diagnosed Philadelphia chromosome-negative (Ph-) acute B-cell lymphoblastic leukemia (B-ALL) patients aged 18-60 years.
- Trial name
- NCT06930105
- Testing
- Blinatumomab plus Reduced-dose Chemotherapy
- Volunteers
- 45 people
- Sponsor
- Xianmin Song, MD
Multiple Myeloma
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
- Trial name
- NCT06105554
- Testing
- Belumosudil mesylate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia (AML)
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60…
- Trial name
- BIG-1 (NCT02416388)
- Testing
- Idarubicin, Daunorubicin, HD Cytarabine
- Where
- 56 sites in France
- Volunteers
- 3,100 people
- Sponsor
- University Hospital, Angers
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
- Trial name
- NCT06395103
- Testing
- Zilovertamab vedotin
- Where
- 71 sites in United States, Australia and 21 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematological Malignancies
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell…
- Trial name
- NCT04959903
- Testing
- Allogeneic T cell progenitors, cultured ex-vivo
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Smart Immune SAS
Hematological Malignancies
Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies
Clinical study on the safety and effectiveness of NK cells/combined monoclonal antibodies in the treatment of hematological malignancies
- Trial name
- NCT04662788
- Testing
- NK cells/Combined Monoclonal Antibodies
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University